Table 1.
Clinical characteristics and treatments
| Overall | Vaccinees | Non-vaccinees | P value | |
| Characteristics | ||||
| Number of patients | 2048 | 1518 | 530 | — |
| Median age, years | 59.0 (54.0–66.0) | 59.0 (54.0–66.0) | 59 (52.0–66.0) | 0.821 |
| Gender | — | — | — | 0.579 |
| Male | 1483 (72.4) | 1079 (71.1) | 404 (76.2) | — |
| Female | 565 (27.6) | 439 (28.9) | 126 (23.8) | — |
| ECOG | — | — | — | <0.001 |
| <2 | 1428 (69.7) | 1120 (73.8) | 308 (58.1) | — |
| ≥2 | 620 (30.3) | 398 (26.2) | 222 (41.9) | — |
| History of COVID-19 infection | 13 (0.6) | 7 (0.5) | 4 (0.8) | 0.112 |
| Number of vaccination shots | — | 2844 | — | — |
| 1 shot | — | 288 (19.0) | — | — |
| 2 shots | — | 1134 (74.7) | — | — |
| 3 shots | — | 96 (6.3) | — | — |
| Adverse effect of vaccination | — | 483 (31.8) | — | — |
| Muscle pain | — | 307 (20.2) | — | — |
| Fever | — | 168 (11.1) | — | — |
| Pneumonia | — | 8 (0.5) | — | — |
| Comorbidities | 462 (22.6) | 277 (18.2) | 185 (34.9) | <0.001 |
| Hypertension | 208 (10.2) | 119 (7.8) | 89 (16.8) | — |
| Diabetes | 63 (3.1) | 45 (3.0) | 18 (3.4) | — |
| Heart disease | 44 (2.1) | 31 (2.0) | 13 (2.5) | … |
| Cerebral infarction | 33 (1.6) | 22 (1.4) | 11 (2.1) | |
| Others | 114 (5.6) | 60 (6.6) | 54 (10.2) | … |
| Cancer types | … | |||
| Lung | 722 (35.3) | 562 (37.0) | 160 (30.2) | 0.041 |
| Liver | 469 (22.9) | 337 (22.2) | 132 (24.9) | 0.208 |
| Intestinal tract | 218 (10.6) | 189 (12.5) | 29 (5.5) | <0.001 |
| Urinary system | 84 (4.1) | 62 (4.1) | 22 (4.2) | 1.000 |
| Nasopharyngeal | 76 (3.7) | 58 (3.8) | 18 (3.4) | 0.790 |
| Others | 479 (23.4) | 310 (20.4) | 169 (31.9) | <0.001 |
| Cancer stages | — | — | — | 0.815 |
| Non-metastasis stage | 24 (1.2) | 19 (1.3) | 5 (0.9) | — |
| Metastasis stage | 2024 (98.8) | 1499 (98.7) | 525 (99.1) | — |
| Treatments | ||||
| Therapy | ||||
| Camrelizumab (Cam) | 903 (44.1) | 670 (44.1) | 233 (44.0) | 0.960 |
| Cam+chemotherapy | 908 (44.3) | 711 (46.8) | 197 (37.2) | <0.001 |
| Cam+targeted therapy | 211 (10.3) | 120 (7.9) | 91 (17.2) | <0.001 |
| Cam+radiotherapy | 26 (1.3) | 17 (1.1) | 9 (1.7) | 0.366 |
| Immune-related adverse events | 719 (35.1) | 585 (38.5) | 134 (25.3) | — |
| ≤2 | 645 (31.5) | 540 (35.6) | 105 (19.8) | <0.001 |
| ≥3 | 74 (3.6) | 45 (3.0) | 29 (5.5) | 0.007 |
| Treatment efficacy | ||||
| Complete remission | 118 (5.8) | 96 (6.3) | 22 (4.2) | 0.066 |
| Partial remission | 438 (21.4) | 307 (20.2) | 131 (24.7) | 0.031 |
| Stable disease | 895 (43.7) | 693 (45.7) | 202 (38.1) | 0.003 |
| Progression disease | 597 (29.2) | 422 (27.8) | 175 (33.0) | 0.026 |
| Overall response rate | 556 (27.1) | 403 (38.0) | 153 (28.9) | 0.308 |
| Disease control rate | 1451 (70.8) | 1096 (72.2) | 355 (67.0) | 0.026 |
| Treatment pause | 221 (10.8) | 113 (7.4) | 108 (20.4) | <0.001 |
ECOG, Eastern Cooperative Oncology Group.